New Clinical Trial Reporting Bill Risks Spooking Investors

Law360, New York (August 3, 2012, 8:54 PM EDT) -- A new bill aimed at broadening the amount of clinical trial data available on the government's public database would expose early data to drug and device sponsors' investors and competitors, potentially scaring off capital or revealing business strategies, experts say.

Led by Rep. Ed Markey, D-Mass., several Democrats introduced a bill Thursday that potentially would add reams of new data to the database by expanding reporting requirements to Phase I trials and studies performed outside the U.S. that are used to support U.S. Food and...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.